Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
Why Novartis CEO was willing to pay top dollar for Avidity
Novartis may have signed off on the second-largest pharma acquisition of 2025, but, as the company’s CEO sees it—it’s never about the price tag.
James Waldron
Nov 20, 2025 4:37am
Novartis' resistance-busting malaria drug hits phase 3 goal
Nov 13, 2025 7:05am
Novartis’ phase 3 wins in Sjögren's see high placebo effect
Oct 29, 2025 12:03pm
Novartis pays $12B for late-stage dystrophy biotech Avidity
Oct 26, 2025 4:01pm
US VC launches another biotech with China-licensed asset
Sep 17, 2025 10:30am
Sanofi becomes latest pharma to hold fire on UK R&D investments
Sep 15, 2025 10:14am
